HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Returns To 'Model' For Success, Expects Surprises From 2020 Launches

Executive Summary

Perrigo "walked away a little bit" from "a model that worked beautifully," says CEO Murray Kessler at investor conference, "In essence, all we've done over the last year is to put back in place the model that worked so well."

You may also be interested in...



Perrigo Launches OTC Viagra Rival In UK

Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect.

Perrigo To Launch UK Private-Label Viagra Connect Competitor

Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect. 

Perrigo Exploring The CBD Opportunity

Perrigo doesn't want to miss out on the opportunity presented by CBD to offer consumers a new type of self-care product, according to the firm’s managing director, UK & Ireland, and International vice president, Neil Lister.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel